Authors:
Gururangan, S
Cokgor, I
Rich, JN
Edwards, S
Affronti, ML
Quinn, JA
Herndon, JE
Provenzale, JM
McLendon, RE
Tourt-Uhlig, S
Sampson, JH
Stafford-Fox, V
Zaknoen, S
Early, M
Friedman, AH
Friedman, HS
Citation: S. Gururangan et al., Phase I study of Gliadel (TM) wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas, NEURO-ONCOL, 3(4), 2001, pp. 246-250
Authors:
Winkelstein, BA
McLendon, RE
Barbir, A
Myers, BS
Citation: Ba. Winkelstein et al., An anatomical investigation of the human cervical facet capsule, quantifying muscle insertion area, J ANAT, 198, 2001, pp. 455-461
Citation: Tj. Cummings et al., Pathologic quiz case - Pituitary mass in a 48-year-old woman - Pathologic diagnosis: Granular cell tumor of the infundibulum, ARCH PATH L, 125(2), 2001, pp. 299-300
Citation: Tj. Cummings et al., CD34 and dural fibroblasts: the relationship to solitary fibrous tumor andmeningioma, ACT NEUROP, 102(4), 2001, pp. 349-354
Authors:
Heimberger, AB
Archer, GE
McLendon, RE
Hulette, C
Friedman, AH
Friedman, HS
Bigner, DD
Sampson, JH
Citation: Ab. Heimberger et al., Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats, CLIN CANC R, 6(10), 2000, pp. 4148-4153
Authors:
Cokgor, I
Akabani, G
Kuan, CT
Friedman, HS
Friedman, AH
Coleman, RE
McLendon, RE
Bigner, SH
Zhao, XG
Garcia-Turner, AM
Pegram, CN
Wikstrand, CJ
Shafman, TD
Herndon, JE
Provenzale, JM
Zalutsky, MR
Bigner, DD
Citation: I. Cokgor et al., Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas, J CL ONCOL, 18(22), 2000, pp. 3862-3872
Authors:
Friedman, HS
Pluda, J
Quinn, JA
Ewesuedo, RB
Long, L
Friedman, AH
Cokgor, I
Colvin, OM
Haglund, MM
Ashley, DM
Rich, JN
Sampson, J
Pegg, AE
Moschel, RC
McLendon, RE
Provenzale, JM
Stewart, ES
Tourt-Uhlig, S
Garcia-Turner, AM
Herndon, JE
Bigner, DD
Dolan, ME
Citation: Hs. Friedman et al., Phase I trial of carmustine plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma, J CL ONCOL, 18(20), 2000, pp. 3522-3528
Authors:
Akabani, G
Cokgor, I
Coleman, RE
Trotter, DG
Wong, TZ
Friedman, HS
Friedman, AH
Garcia-Turner, A
Herndon, JE
DeLong, D
McLendon, RE
Zhao, XG
Pegram, CN
Provenzale, JM
Bigner, DD
Zalutsky, MR
Citation: G. Akabani et al., Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy, INT J RAD O, 46(4), 2000, pp. 947-958
Authors:
Heimberger, AB
Crotty, LE
Archer, GE
McLendon, RE
Friedman, A
Dranoff, G
Bigner, DD
Sampson, JH
Citation: Ab. Heimberger et al., Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma, J NEUROIMM, 103(1), 2000, pp. 16-25
Authors:
Cummings, TJ
Provenzale, JM
Hunter, SB
Friedman, AH
Klintworth, GK
Bigner, SH
McLendon, RE
Citation: Tj. Cummings et al., Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis, ACT NEUROP, 99(5), 2000, pp. 563-570
Authors:
Nuckols, JD
Liu, K
Burchette, JL
McLendon, RE
Traweek, ST
Citation: Jd. Nuckols et al., Primary central nervous system lymphomas: A 30-year experience at a singleinstitution, MOD PATHOL, 12(12), 1999, pp. 1167-1173
Authors:
Friedman, HS
Petros, WP
Friedman, AH
Schaaf, LJ
Kerby, T
Lawyer, J
Parry, M
Houghton, PJ
Lovell, S
Rasheed, K
Cloughsey, T
Stewart, ES
Colvin, OM
Provenzale, JM
McLendon, RE
Bigner, DD
Cokgor, I
Haglund, M
Rich, J
Ashley, D
Malczyn, J
Elfring, GL
Miller, LL
Citation: Hs. Friedman et al., Irinotecan therapy in adults with recurrent or progressive malignant glioma, J CL ONCOL, 17(5), 1999, pp. 1516-1525